21 CFR Part 1271 · Human Cells, Tissues, and Cellular and Tissue-Based Products

21 CFR 1271.320

Complaint file

21 CFR 1271.320 is the regulation titled “Complaint file” in 21 CFR Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products. Since 2021, 1 FDA warning letter has cited it.

Letters citing it
1 since 2021
Jan 1 to Oct 30, 2026
0 against 0 on the same dates in 2025
Most often cited with
21 CFR 1271.180, in 1 letter
Closed out
0% of these letters have a published close-out
See the letter citing 21 CFR 1271.320 →

Letters citing it, by year issued

It is a biologics letter. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 12021
  2. 02022
  3. 02023
  4. 02024
  5. 02025
  6. 02026

The regulation

Read the text of 21 CFR 1271.320 (eCFR, as of Sep 1, 2026)

(a) Procedures. You must establish and maintain procedures for the review, evaluation, and documentation of complaints as defined in § 1271.3(aa), relating to core current good tissue practice (CGTP) requirements, and the investigation of complaints as appropriate.

(b) Complaint file. You must maintain a record of complaints that you receive in a file designated for complaints. The complaint file must contain sufficient information about each complaint for proper review and evaluation of the complaint (including the distinct identification code of the HCT/P that is the subject of the complaint) and for determining whether the complaint is an isolated event or represents a trend. You must make the complaint file available for review and copying upon request from FDA.

(c) Review and evaluation of complaints. You must review and evaluate each complaint relating to core CGTP requirements to determine if the complaint is related to an HCT/P deviation or to an adverse reaction, and to determine if a report under § 1271.350 or another applicable regulation is required. As soon as practical, you must review, evaluate, and investigate each complaint that represents an event required to be reported to FDA, as described in § 1271.350. You must review and evaluate a complaint relating to core CGTP requirements that does not represent an event required to be reported to determine whether an investigation is necessary; an investigation may include referring a copy of the complaint to another establishment that performed manufacturing steps pertinent to the complaint. When no investigation is made, you must maintain a record that includes the reason no investigation was made, and the name of the individual(s) responsible for the decision not to investigate.

Text from eCFR as of Sep 1, 2026.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 1271.320.

Latest letters citing it

The letter citing 21 CFR 1271.320 that FDA posted most recently.

See the letter citing 21 CFR 1271.320 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.